References
- Schwallie P C. Experience with Depo-provera as an injectable contraceptive. J Reprod Med 1974; 13: 113–117
- Grundy S M, Garber A, Goldberg R, Havas S, Holman R, Lamendola C, Howard W J, Savage P, Sowers J, Vega G L. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors. Circulation 2002; 105: e153–e158
- Carr M E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44–54
- Garg S K, Chase H P, Marshall G, Hoops S L, Holmes D L, Jackson W E. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. J Am Med Assoc 1994; 271: 1099–1102
- Klein B EK, Moss S E, Klein R. Oral contraceptives in women with diabetes. Diabetes Care 1990; 13: 895–898
- Family and Reproductive Health Programme. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. 2nd ed. World Health Organization, Geneva 2000
- Kimmerle R, Weiss R, Berger M, Kurz K H. Effectiveness, safety, and acceptability of a copper intrauterine device (CU Safe 300) in type I diabetic women. Diabetes Care 1990; 16: 1227–1230
- Skouby S O, Molsted-Pedersen L, Kosonen A. Consequences of intrauterine contraception in diabetic women. Fertil Steril 1984; 42: 568–572
- Andersson K. The levonorgestrel intrauterine system: more than a contraceptive. Eur J Contracept Reprod Health Care 2001; 6: 15–22
- Rogovskaya S, Rivera R, Grimes D A, Chen P L, Pierre-Louis B, Prilepskaya V, Kulakov V. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 2005; 105: 811–815
- Andersson K, Stadberg E, Mattsson L A, Rybo G, Samsioe G. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women – effects on lipid metabolism during 12 months of treatment. Int J Fertil Menopausal Stud 1996; 41: 476–483
- Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, Timonen H, Riphagen F, Laatikainen T. Intrauterine 10 μg and 20 μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2002; 109: 136–144
- Wollter-Svensson L O, Stadberg E, Andersson K, Mattsson L A, Odlind V, Persson I. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. Maturitas 1995; 22: 199–205